REINACH, Switzerland, April 25 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that Dr Jurgen Raths will succeed Dr Khalid Islam as Chief Executive Officer. Dr Jurgen Raths commands extensive knowledge in the commercialisation of drugs for the treatment of severe infections in hospitals and has successfully built and lead the European Critical Care sales, medical and marketing organisation of Eli Lilly and Company for many years.
At the Annual General Meeting of 7 May, the Board of Directors will propose to appoint Dr Khalid Islam to the Board of Directors of Arpida Ltd. Dr Islam will work closely with Dr Raths for a seamless transition and will continue thereafter as a consultant for the coming years. As a result, his experience and expertise in the anti-infective area and his thorough knowledge of Arpida's programmes will continue to be available to the company. Dr Raths, a member of the Arpida board since 2006, will assume his responsibilities as CEO on 1 May 2008 focusing during the first two months on deepening his knowledge of the company and getting to know Arpida's shareholders and business partners.
Dr Andre Lamotte, Chairman of the Board of Directors of Arpida Ltd., commented: "Arpida's Board, employees, shareholders and business partners owe a lot to Khalid Islam. His outstanding leadership, unwavering energy and deep knowledge have been crucial for Arpida's progress over the past nine years. On behalf of Arpida's Board and staff, I would like to thank Khalid for his vital contributions. I am very pleased that he will continue to serve Arpida both in his function as a board member as well as in his active advisory role going forward. I am particularly delighted and convinced that Jurgen Raths' extensive knowledge of successfully building and managing sales organisations will enable Arpida to move into the next important phase of becoming a fully integrated pharmaceutical company."
Dr Khalid Islam commented, "I
|SOURCE Arpida Ltd|
Copyright©2008 PR Newswire.
All rights reserved